Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.
T he immune checkpoint molecules cytotoxic T-lymphocyteeassociated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) are critical in controlling T-cell activation and promoting self-tolerance by down-modulation of T-cell activity upon interaction with their ligands. 1 In turn, their inhibition permits up-regulation of T-cell activation and impairs self-tolerance, which, in the cancer-bearing host, can lead to robust antitumor immunity. 1, 2 Immune checkpoint inhibitors (ICIs) target CTLA-4, PD-1, and the programmed cell death ligand 1 (PD-L1) and are approved for the treatment of advanced melanoma, selected lymphomas, and advanced nonesmall cell lung cancer. These medications are the first to improve overall survival in patients with advanced melanoma. By virtue of their mechanism of action, ICIs are commonly associated with adverse events, including immune-related adverse events (irAEs), which manifest as systemic and organ-specific autoimmunity and pose a challenge in treatment. 3 Dermatologic adverse events are among the most commonly reported toxicities of ICI therapy. They include rash, pruritus, dermatitis, photosensitivity, urticaria, toxic epidermal necrolysis, and vitiligo. 4 Arthralgia and myalgia are the most reported rheumatic and musculoskeletal irAEs. 5 Inflammatory arthritis, sicca syndrome, vasculitis, myositis, and polymyalgia rheumatica have been reported in the past few years.
6-9
We present 2 patients in whom scleroderma developed after treatment with pembrolizumab, a PD-1 inhibitor, of metastatic melanoma. We recently reported on patient 2 as the first published case of a sclerodermoid reaction to pembrolizumab. 10 The emergence of a second case of a sclerosing skin process induced by pembrolizumab with systemic features within the same institution warrants broad reporting to health care professionals to increase their awareness and to help improve management.
CASE REPORTS

Patient 1
A 66-year-old man, previously treated with pembrolizumab for BRAF (B-Raf protooncogene, serine/threonine kinase)epositive stage IV metastatic melanoma, was referred to our rheumatology service for weakness, profound fatigue, and skin stiffness. Soon after the melanoma diagnosis 1 year earlier, he began therapy with pembrolizumab 2 mg/kg every 3 weeks. After cycle 13 of pembrolizumab, fatigue developed along with swelling of his joints and ankles. After cycle 14, his symptoms progressed and included skin dryness and burning and muscle weakness. Pembrolizumab therapy was discontinued, and he began taking prednisone 1 mg/kg daily. His weakness continued to progress along with new-onset diffuse skin tightness. Review of systems was negative for Raynaud phenomenon, gastroesophageal reflux, dysphagia, diarrhea, and shortness of breath.
On physical examination, the patient was confined to a wheelchair and required considerable assistance to reach the examination table. He had marked xerosis and moderate to severe skin tightness with thickening involving the forearms, hands, fingers, thighs, legs, feet, and face ( Figure 1 ). The modified Rodnan skin score (mRSS) was 36. He did not have nailfold capillary abnormalities. Wrist and shoulder range of motion was limited bilaterally. The patient had diminished muscle bulk with atrophy of the deltoids and quadriceps. No synovitis or tendon friction rubs were noted. Specimens from 2 skin punch biopsies (right upper forearm and right medial shin) revealed mild dermal fibrosis and sclerosis with trapping of adnexal structures and minimal lymphocytic inflammation, compatible with a sclerosing process (Figure 1) .
The laboratory test results revealed a normal erythrocyte sedimentation rate, mildly elevated C-reactive protein level, and normal levels of antinuclear, anticentromere, antiribonucleoprotein, and antietopoisomerase 1 (Scl 70) antibodies. Anti-RNA polymerase III (RNAP3) was not tested. Muscle enzyme levels were within the reference ranges. 
PEMBROLIZUMAB-INDUCED SCLERODERMA
Electromyography revealed sensorimotor polyneuropathy, primarily axonal, without evidence of myopathy. Muscle biopsy was not performed. The patient was given a diagnosis of diffuse scleroderma, secondary to pembrolizumab.
Treatment was initiated with intravenous immunoglobulin, 0.4 mg/kg daily for 5 days monthly, and mycophenolate mofetil, 1000 mg twice daily. Within 8 weeks, the patient's prednisone therapy was tapered and then discontinued; his local oncologist reported that the patient had subjective improvement in his skin changes, particularly in the hands and lower extremities (no mRSS was provided). The patient could ambulate with assistance, although subjectively he continued to feel weak and fatigued. The plan was to continue therapy with intravenous immunoglobulin and mycophenolate mofetil for 3 to 6 months with close rheumatologic followup. This was a shorter treatment course than would be expected because of concern for prolonged immunosuppression and an increased risk of cancer recurrence. The patient did not resume pembrolizumab treatment, but his melanoma was found to be in complete remission. However, 14 weeks after initiating intravenous immunoglobulin and mycophenolate, the patient had worsening diffuse muscle weakness, profound fatigue, and loss of appetite. Further work-up was recommended, but the patient declined and began hospice care. He died 2 months later of unknown causes (autopsy was declined).
Patient 2
A 79-year-old man, receiving pembrolizumab therapy for BRAF wild-type stage IV metastatic melanoma, was referred to a dermatologist for subacute onset of skin changes and stiffness involving his hands and feet. When the diagnosis of metastatic melanoma was established 5 months earlier, the patient began treatment with pembrolizumab, 2 mg/kg daily every 3 weeks. Shortly after cycle 5 of pembrolizumab, he began having severe stiffness of his hands and feet, with difficulty grasping objects and ambulating. Specimens from 2 skin punch biopsies (left ventral wrist and right dorsal hand) revealed mild perivascular lymphocytic inflammation and deep dermal sclerosis, consistent with a sclerodermoid reaction ( Figure 2) . He was prescribed hydroxychloroquine by a dermatologist and prednisone (1 mg/kg) by his oncologist. One month later, the patient had some improvement in the acral stiffness, but when the corticosteroid therapy was tapered, hand stiffness recurred and weakness and shortness of breath developed. He was referred to a rheumatologist. During evaluation, the recent onset of Raynaud phenomenon involving the second through fifth digits bilaterally was noted. Review of systems was negative for gastroesophageal reflux, dysphagia, and diarrhea. Physical examination was notable for bilateral edema with moderate skin tightness and thickening involving the wrists, hands, fingers, and dorsal surfaces of the feet (mRSS, 12) (Figure 2 ), periungual erythema, mildly dilated nailfold capillaries, and inspiratory crackles at the left lung base. No synovitis or tendon friction rubs were noted.
As with patient 1, the laboratory test results for patient 2 revealed normal erythrocyte sedimentation rate, mildly elevated C-reactive protein level, and negative antinuclear, anticentromere, anti-ribonucleoprotein, and antietopoisomerase 1 antibodies. Anti-RNAP3 was not tested. Transthoracic echocardiographic findings were within normal limits, with no elevation in right ventricular systolic pressure. Computed tomography of the lungs revealed patchy ground-glass infiltrates in the lower lung fields. Pulmonary function test results revealed borderline desaturation with exercise but was otherwise normal, without reduced diffusing capacity or evidence of any restrictive process. Transthoracic echocardiography revealed no evidence of pulmonary hypertension, with normal estimated right ventricular systolic pressure. Muscle enzyme test results were negative for inflammatory myositis. Electromyography and muscle biopsy were not performed. The diagnosis was limited scleroderma, secondary to pembrolizumab and pembrolizumab-induced pneumonitis.
Pembrolizumab therapy was discontinued. The patient continued to receive hydroxychloroquine (200 mg twice daily) and oral prednisone, with plans for a rapid taper. Within 3 weeks, his fatigue, shortness of breath, and acral stiffness improved considerably, and follow-up computed tomography of the lung revealed a decrease in ground-glass infiltrates. He was seen by a dermatologist within 12 weeks and was found to have persistent but improving skin tightness, now predominantly involving the hands and fingers (mRSS, 8). Pembrolizumab therapy has not been reinitiated. The patient is undergoing radiotherapy for hepatic metastasis.
DISCUSSION
Numerous regulatory mechanisms control T lymphocytes, especially to eliminate selfreactivity. Cytotoxic T-lymphocyteeassociated protein 4 and PD-1/PD-L1 are distinct checkpoint pathways modulating T-cell immune response.
1,2 The CTLA-4 pathway inhibits early self-reactive T cells in lymph nodes; the PD-1 pathway inhibits T cells already activated in peripheral tissues. 2 Monoclonal antibodies blocking CTLA-4 or PD-1/PD-L1 allow for increased T-cell activity and antitumor effect, leading to their use as effective cancer therapy. 2 Ipilimumab (targets CTL-4), pembrolizumab (targets PD-1), and nivolumab (targets PD-1) are ICIs with reported survival benefit 2 that are currently approved by the US Food and Drug Administration for the treatment of unresectable or metastatic melanoma. Potential adverse effects include irAEs. 7, 11 Immunerelated adverse events most commonly affect the digestive, dermal, musculoskeletal, and endocrine systems, with severity graded from 1 to 5 (1, mild; 2, moderate; 3, severe; 4, life-threatening; and 5, death-associated). In a phase 3 controlled trial comparing ipilimumab with pembrolizumab for advanced melanoma, adverse events occurred in 73% to 80% of patients receiving pembrolizumab and in 73% of those receiving ipilimumab. 12 The incidence of adverse events with severity grades of 3 to 5 was higher with ipilimumab (20%) than with pembrolizumab (10%-13%). The predominant cutaneous and rheumatologic irAEs reported with pembrolizumab therapy included pruritus (14%), rash (13%-15%), vitiligo (9%-11%), myalgia (2%-7%), arthralgia (9%-12%), and arthritis (<1%). 7, 12 The most common irAEs with ipilimumab were pruritus (25%-35%), rash (15%-21%), vitiligo (2%-4%), myalgia (2%), and arthralgia (5%). 7, 12, 13 There are rare reports 7, 8, 14, 15 of patients having more serious dermatologic adverse events, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, Sweet syndrome, and drug reaction with eosinophilia and systemic symptoms. Rheumatic irAEs are increasingly being recognized in recent reports of inflammatory arthritis and sicca syndrome. 5, 6 A few case reports [7] [8] [9] have been published on vasculitis, polymyositis, dermatomyositis, temporal arteritis, or polymyalgia rheumatica.
Most irAEs develop within 3 to 6 months of the initiation of ICI therapy, are responsive to systemic corticosteroids (0.5-2 mg/kg daily, depending on severity of symptoms), and can improve within 3 months but can often take much longer to resolve. 11, 16 We do acknowledge that high-dose corticosteroids are not recommended in the management of scleroderma owing to concern for precipitation of scleroderma renal crisis. However, corticosteroids are currently the treatment mainstay for irAEs and were therefore quickly initiated by the treating oncologists in both our patients before the diagnosis of scleroderma was confirmed. Neither hypertension nor scleroderma renal crisis developed in our 2 patients; however, health care professionals should remain vigilant for these complications. Ideally, in this clinical scenario, corticosteroid exposure should be limited, with plans for a rapid taper, and a corticosteroid-sparing agent should be used early in the disease course, if possible.
Indeed, if the irAE is refractory to corticosteroids, patients may need immunosuppressive or modulatory therapies, such as azathioprine, mycophenolate mofetil, cyclosporine, and tumor necrosis factor a inhibitors. 7, 11 In 1 study, 17 up to one-third of patients who were treated with ipilimumab and had an irAE required immunosuppressive therapy in addition to corticosteroids. Importantly, the authors of that study found that overall survival and treatment failure were not affected by the occurrence or treatment of an irAE. Another study 18 investigating ipilimumab did not find marked differences in disease control and survival between patients with irAEs and those without irAEs. It remains unclear whether development of irAEs correlates with ICI efficacy. For our patients, the diagnosis of scleroderma induced by pembrolizumab was based on the pattern of skin involvement and characteristic examination, supportive skin biopsies, and the temporal relationship with ICI therapy. Notably, both patients were older white men without any known personal or family history of rheumatologic or autoimmune disease and without any characteristic autoantibodies. RNA polymerase III was not tested for either of our patients. Although there is a well-established association of positive anti-RNAP3 with increased cancer risk in systemic sclerosis, 19, 20 no reports of melanoma associated with scleroderma or positive anti-RNAP3 were identified. Therefore, we postulate that it is unlikely that scleroderma in our patients was directly associated with metastatic melanoma.
The pathophysiologic mechanism of the PD-1 inhibitor leading to cutaneous sclerosis is unknown. Given the pathogenic link between transforming growth factor b and systemic sclerosis, 21 one could postulate that widespread inflammation induced by PD-1 inhibition in patients with melanoma could lead to localized transforming growth factor b activation within the skin, subsequently initiating a profibrotic cascade resulting in a scleroderma phenotype.
CONCLUSION
Immune checkpoint inhibitors are beneficial in cancer treatment, and they improve survival in advanced melanoma. As their use grows exponentially, new irAEs are increasingly reported, including rheumatic and musculoskeletal events. An area ripe for further investigation is translational study of patients who have irAEs, which may shed light on the pathophysiology of the manifesting autoimmune disease.
Health care professionals must be aware of irAEs, carefully monitor patients, and make swift referrals to subspecialists. Prompt recognition and treatment of irAEs may improve tolerance to ICIs and increase cancer survival. 
